Tonix Pharmaceuticals Holding Corp. — 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. Tonix is a clinical-stage biopharmaceutical company; it reported no approved products or product-sale revenue.
Financial performance and liquidity
- Revenue and margins: No product revenue was reported. Gross margin is not applicable to the reported results.
- Expenses and losses: Research and development expense was $68.8 million, up 90% from $36.2 million in 2020. General and administrative expense was $23.5 million, up 63% from $14.4 million. Operating loss was $92.3 million versus $50.5 million; net loss was $92.3 million versus $50.5 million. Basic and diluted loss per share was $0.26 versus $0.55, with weighted-average shares rising to 360.2 million from 94.6 million.
- Cash flow: Operating cash use was $75.6 million versus $48.6 million; investing cash use was $35.3 million versus $8.6 million, primarily for property and equipment. Financing provided $212.5 million versus $123.1 million, largely through equity issuance and warrant exercises.
- Liquidity: Cash and cash equivalents were $178.7 million at year-end, compared with $77.1 million; working capital was $167.3 million. Total liabilities were $22.2 million, including $1.0 million of lease liabilities. The filing reports no material borrowings or debt balance.
- Capital spending and commitments: Property and equipment was $50.6 million, including $41.9 million in construction in progress. Outstanding commitments included approximately $47.9 million for contract research work and $30.1 million for construction.
Material changes and notable developments
- Research and development spending increased substantially, with higher nonclinical, manufacturing, employee-related and regulatory costs. The company also expanded infrastructure for infectious-disease research and vaccine development.
- Common shares issued and outstanding rose to 496.2 million at year-end from 206.0 million a year earlier. The company reported 533.9 million shares outstanding as of March 14, 2022, reflecting continued equity financing and dilution.
- TNX-102 SL’s Phase 3 RELIEF fibromyalgia trial met its primary endpoint in 2020, but the separate Phase 3 RALLY study was stopped for futility at interim analysis in 2021. Topline RALLY results were expected in early 2022, followed by a planned new Phase 3 trial.
- TNX-102 SL’s Phase 3 RECOVERY PTSD study did not meet its primary endpoint. Tonix planned a Phase 2 study using a revised endpoint approach.
- Other pipeline plans included Phase 1 development of TNX-1500, a Phase 2 safety study of TNX-1300, and Phase 2 studies of TNX-1900 and TNX-102 SL for Long COVID. These were forward-looking plans, not completed milestones.
Outlook, risks and unusual items
- Going concern: The auditor’s report includes an explanatory paragraph citing substantial doubt about Tonix’s ability to continue as a going concern, driven by recurring losses and negative operating cash flows. Management said year-end cash plus first-quarter 2022 equity proceeds were expected to fund operations through the end of 2022, but not beyond. The filing also states the company would not have sufficient resources for the one-year period from the filing date without additional funding. Additional capital may be required; unavailable or unfavorable financing could lead to program delays, reductions or curtailment.
- Financing and dilution: 2021 financing included $65.0 million net proceeds from a February offering, $69.3 million from at-the-market sales and approximately $41.3 million gross proceeds under a Lincoln Park purchase agreement. After year-end, reported sales generated approximately $4.3 million net under the ATM and $4.5 million net under a separate Lincoln Park agreement.
- Regulatory and clinical risk: All product candidates remain investigational. Clinical outcomes, regulatory decisions, manufacturing readiness, reimbursement and market acceptance remain uncertain; past positive early or animal results do not assure approval or commercial success.
- Listing risk: The company disclosed failure to meet Nasdaq’s $1 minimum bid-price requirement and a second compliance period, with a reverse stock split identified as a possible remedy. The filing reported a March 11, 2022 closing price of $0.22.
- Facilities and spending: Several planned research and manufacturing facilities were not ready for intended use at year-end. Execution, construction costs and the substantial contractual commitments could increase cash needs.
Key facts for investors to verify
- Current cash, subsequent financing proceeds, expected cash runway and any updated going-concern disclosures.
- Final RALLY results and the status, design and timing of any further fibromyalgia trial; assess these alongside the positive RELIEF result.
- Progress and regulatory feedback for TNX-1500, TNX-1300, TNX-102 SL Long COVID and other planned studies.
- Share count, remaining equity-facility capacity, potential future issuance and resulting dilution; also verify Nasdaq listing compliance.
- Actual completion, operational readiness and total remaining costs for the research and vaccine-manufacturing facilities, and the timing of committed contract and construction payments.